GNLX · Genelux Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $8.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.78M | - | $4.74M | $4.76M | $4.70M | - | $4.05M | $4.42M | $4.01M | - |
| SG&A | $3.39M | - | $3.45M | $3.03M | $3.12M | - | $2.89M | $2.48M | $4.11M | - |
| Total Operating Expenses | $9.17M | - | $8.19M | $7.79M | $7.82M | - | $6.94M | $6.89M | $8.12M | - |
| D&A | $9.0K | - | $61.0K | - | $59.0K | - | - | - | $84.0K | - |
| Operating Income | ($9.17M) | - | ($8.19M) | ($7.79M) | ($7.82M) | - | ($6.94M) | ($6.89M) | ($8.12M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($8.93M) | - | ($7.95M) | ($7.46M) | ($7.49M) | - | ($6.47M) | ($6.58M) | ($7.85M) | - |
| EPS - Basic | ($0.20) | - | ($0.21) | ($0.20) | ($0.21) | - | ($0.19) | ($0.22) | ($0.29) | - |
| EPS - Diluted | ($0.20) | - | ($0.21) | ($0.20) | ($0.21) | - | ($0.19) | ($0.22) | ($0.29) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.27M | $5.33M | $4.69M | $6.55M | $16.21M | $8.56M | $6.10M | $7.86M | $4.06M | $9.42M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $26.75M | $15.13M | $21.55M | $29.23M | $35.95M | $31.55M | $35.97M | $34.87M | $21.20M | $24.20M |
| Total Assets | $32.37M | $19.03M | $24.99M | $32.25M | $38.98M | $34.72M | $40.27M | $45.18M | $24.68M | $27.89M |
| Current Liabilities | $7.27M | $6.22M | $5.13M | $6.99M | $7.69M | $6.90M | $5.55M | $5.80M | $7.80M | $6.55M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $9.45M | $7.48M | $6.40M | $8.35M | $9.14M | $8.44M | $7.18M | $7.51M | $9.59M | $8.42M |
| Stockholders' Equity | $22.92M | $11.54M | $18.59M | $23.90M | $29.85M | $26.27M | $33.09M | $37.67M | $15.08M | $19.47M |
| Retained Earnings | ($292.47M) | ($283.54M) | ($274.29M) | ($266.34M) | ($258.88M) | ($251.39M) | ($242.42M) | ($235.95M) | ($229.37M) | ($221.52M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.06M) | - | - | - | ($5.43M) | - | - | - | ($4.35M) | - |
| Investing Cash Flow | ($8.54M) | - | - | - | $3.51M | - | - | - | ($1.69M) | - |
| Financing Cash Flow | $18.54M | - | - | - | $9.57M | - | - | - | $688.0K | - |
| CapEx | $921.0K | - | - | - | $30.0K | - | - | - | $30.0K | - |
| Free Cash Flow | ($6.98M) | - | - | - | ($5.46M) | - | - | - | ($4.38M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | -101437.5% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -100387.5% | - |
| Net margin | - | - | - | - | - | - | - | - | -98125.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -54800.0% | - |
| FCF / Net income | 0.78 | - | - | - | 0.73 | - | - | - | 0.56 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | 50125.0% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | 51412.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -27.6% | - | -31.8% | -23.1% | -19.2% | - | -16.1% | -14.6% | -31.8% | - |
| Return on equity | -39.0% | - | -42.8% | -31.2% | -25.1% | - | -19.5% | -17.5% | -52.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.68 | 2.43 | 4.20 | 4.18 | 4.67 | 4.57 | 6.47 | 6.01 | 2.72 | 3.69 |
| Quick ratio | 3.68 | 2.43 | 4.20 | 4.18 | 4.67 | 4.57 | 6.47 | 6.01 | 2.72 | 3.69 |
| Cash ratio | 1.28 | 0.86 | 0.92 | 0.94 | 2.11 | 1.24 | 1.10 | 1.35 | 0.52 | 1.44 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.41 | 1.65 | 1.34 | 1.35 | 1.31 | 1.32 | 1.22 | 1.20 | 1.64 | 1.43 |
| Liabilities / Assets | 0.29 | 0.39 | 0.26 | 0.26 | 0.23 | 0.24 | 0.18 | 0.17 | 0.39 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.7x | - | 8.6x | 4.6x | 3.2x | - | 2.5x | 1.5x | 11.4x | - |
| P / S | - | - | - | - | - | - | - | - | 21580.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | -95.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -17.3% | - | -18.1% | -13.1% | 3.7% | - | - | -27.7% | -25.6% | - |
| Net income growth (YoY) | -19.2% | - | -22.9% | -13.4% | 4.6% | - | -21.0% | -13.0% | -106.5% | - |
| EPS growth (YoY) | 4.8% | - | -10.5% | 9.1% | 27.6% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -27.7% | - | - | - | -24.7% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -23.2% | -56.1% | -43.8% | -36.6% | 97.9% | 34.9% | 37.7% | 69.3% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$8.0K totalOperating And Reportable Segments$8.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing GENELUX Corp against the 5 most active filers in the same SIC group.